Aerska
Aerska54About
What does Aerska do?
Aerska is developing systemically delivered RNA medicines for diseases of the brain. Their approach focuses on precision medicine, utilizing next-generation RNAi and advanced brain shuttle technologies to target the root causes of neurological disorders. The company aims to treat, delay, and prevent these diseases, ultimately preserving minds and enabling healthier, longer lives.
What is Aerska's revenue?
StartupHub estimates Aerska's annual revenue at $5.0M (range $2.7M to $11.6M, 65% confidence), based on comparable companies in the sector.
What is Aerska's valuation?
StartupHub estimates Aerska's effective valuation at $130.6M (range $80.0M to $192.0M, 20% confidence), based on comparable companies in the sector.
How much funding has Aerska raised?
Aerska has raised a total of $32M in funding. The most recent round on record is Unknown.
Where is Aerska headquartered?
Aerska is headquartered in Dublin, Ireland.
When was Aerska founded?
Aerska was founded in 2021.
What industry does Aerska operate in?
Aerska operates in Biotech, Healthcare, Longevity, Drug Discovery, HealthTech, Epigenetic Reprogramming.
How many employees does Aerska have?
Aerska has approximately 23 people on record.
No comments yet. Be the first to share your take.